Apellis Pharmaceuticals (APLS) News Today $27.52 -0.83 (-2.93%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$27.52 0.00 (0.00%) As of 02/21/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Ieq Capital LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Ieq Capital LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1,425.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,710 shares of the company's stock after acquiring an additional 118,404February 22 at 4:33 AM | marketbeat.comIs Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?February 20 at 1:04 PM | msn.comApellis announces EMA validation of Aspaveli indication extension applicationFebruary 20 at 8:03 AM | markets.businessinsider.comApellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNFebruary 20 at 2:00 AM | globenewswire.comApellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In JanuaryFebruary 18, 2025 | msn.comApellis Pharmaceuticals (APLS) to Release Earnings on TuesdayApellis Pharmaceuticals (NASDAQ:APLS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666735)February 18, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest UpdateApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 17,060,000 shares, a drop of 5.4% from the January 15th total of 18,040,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest ratio is currently 6.5 days.February 18, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Position Raised by Banque Pictet & Cie SABanque Pictet & Cie SA raised its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 31.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,299 shares of the companyFebruary 15, 2025 | marketbeat.comSavant Capital LLC Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Savant Capital LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,525 shares of the company's stFebruary 15, 2025 | marketbeat.comApellis Pharmaceuticals' chief business officer sells $10,359 in stockFebruary 14, 2025 | msn.comApellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsFebruary 14, 2025 | globenewswire.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $46.71 Average PT from BrokeragesFebruary 14, 2025 | americanbankingnews.comNvidia Stock Slips. Why Stargate and Meta Are in Focus for Investors.February 13, 2025 | yahoo.comWells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)February 13, 2025 | markets.businessinsider.comApellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past weekFebruary 13, 2025 | uk.finance.yahoo.comRaymond James maintains Strong Buy on Apellis shares, target at $78February 13, 2025 | msn.comApellis Pharmaceuticals (NASDAQ:APLS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Thursday.February 13, 2025 | marketbeat.comEntropy Technologies LP Takes $445,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Entropy Technologies LP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,960 shares of the company's stock, valued at approximatelyFebruary 13, 2025 | marketbeat.comPiper Sandler maintains neutral on Apellis stock, $32 targetFebruary 13, 2025 | msn.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) insider Mark Jeffrey Delong sold 363 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $28.54, for a total transaction of $10,360.02. Following the completion of the sale, the insider now owns 83,945 shares in the company, valued at $2,395,790.30. The trade was a 0.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.February 12, 2025 | marketbeat.comWhy Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) RecentlyFebruary 11, 2025 | msn.comPiper Sandler Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)February 10, 2025 | markets.businessinsider.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from BrokeragesApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nineteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation, ten have issued aFebruary 9, 2025 | marketbeat.comApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comJennison Associates LLC Purchases 939,289 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Jennison Associates LLC lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 51.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,760,404 shares of the company's stock aFebruary 4, 2025 | marketbeat.comShort Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Drops By 16.0%Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) saw a significant decrease in short interest in January. As of January 15th, there was short interest totalling 18,040,000 shares, a decrease of 16.0% from the December 31st total of 21,480,000 shares. Based on an average daily volume of 3,020,000 shares, the short-interest ratio is presently 6.0 days.February 1, 2025 | marketbeat.comKBC Group NV Acquires 101,655 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)KBC Group NV grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,862.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 104,287 shares of the company's stock after acquiringFebruary 1, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $16,117.92 in StockJanuary 31, 2025 | insidertrades.comApellis Pharmaceuticals general counsel sells $20,518 in stockJanuary 31, 2025 | msn.comApellis Pharmaceuticals CFO sells $16,119 in stockJanuary 30, 2025 | msn.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 546 Shares of StockApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CFO Timothy Eugene Sullivan sold 546 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $16,117.92. Following the sale, the chief financial officer now directly owns 128,665 shares in the company, valued at $3,798,190.80. The trade was a 0.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 30, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 695 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 695 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $20,516.40. Following the completion of the sale, the general counsel now directly owns 144,299 shares of the company's stock, valued at $4,259,706.48. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 30, 2025 | marketbeat.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 825 Shares of StockApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) insider Nur Nicholson sold 825 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total transaction of $24,354.00. Following the transaction, the insider now owns 83,664 shares in the company, valued at approximately $2,469,761.28. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.January 30, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 2,824 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CEO Cedric Francois sold 2,824 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the transaction, the chief executive officer now owns 415,695 shares of the company's stock, valued at approximately $12,271,316.40. This represents a 0.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 30, 2025 | marketbeat.comSippican Capital Advisors Has $662,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Sippican Capital Advisors cut its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 31.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,753 shares of the coJanuary 30, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Receives Sector Perform Rating from Royal Bank of CanadaRoyal Bank of Canada restated a "sector perform" rating and set a $26.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday.January 29, 2025 | marketbeat.comApellis Pharmaceuticals, Inc.: Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA)January 28, 2025 | finanznachrichten.deCautious Optimism: Hold Rating for Apellis Pharmaceuticals Amid Slow Financial Impact from Australian Market ExpansionJanuary 28, 2025 | markets.businessinsider.comMizuho maintains Neutral rating on Apellis stock, price target $30January 28, 2025 | msn.comMizuho Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)January 28, 2025 | markets.businessinsider.comAustralia’s TGA approves Apellis’ SYFOVRE for GA related to AMDJanuary 28, 2025 | markets.businessinsider.comApellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)January 27, 2025 | globenewswire.comWhat is Wedbush's Forecast for APLS FY2024 Earnings?Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Wedbush lifted their FY2024 earnings per share estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the company will eJanuary 27, 2025 | marketbeat.comApellis Pharmaceuticals CEO Francois sells $412,295 in stockJanuary 25, 2025 | msn.comApellis Pharmaceuticals executive sells $33,346 in stockJanuary 25, 2025 | msn.comAssenagon Asset Management S.A. Decreases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Assenagon Asset Management S.A. decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 98.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,993 shares of the company's stock after selling 2,114,422 shares during the peJanuary 25, 2025 | marketbeat.comApellis Pharmaceuticals CFO sells shares worth $93,953January 24, 2025 | msn.comApellis Pharmaceuticals executive sells shares worth $42,473January 24, 2025 | msn.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 1,096 SharesJanuary 24, 2025 | insidertrades.comJames George Chopas Sells 1,096 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CAO James George Chopas sold 1,096 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares of the company's stock, valued at approximately $1,464,839.34. This represents a 2.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.January 23, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.520.60▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼98▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News VTRS News MRNA News RDY News PCVX News SRPT News QGEN News ASND News ROIV News RVMD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts